John R. Uhrin
Venture Partner
John R. Uhrin is a Venture Partner for Harbert Venture Partners. Mr. Uhrin joined Harbert Management Corporation (HMC) in 2002 and has more than twenty-five years of experience in the pharmaceutical and biotechnology industries. Mr. Uhrin serves on the board of nContact Surgical and assists several companies through board visitation rights, such as Aldagen, Innovative Biosensors and Maxcyte. He also serves as a board member or advisor to numerous regional life science focused organizations, including the University of Virginia’s Nursing Ventures Board, Southeast BIO, Mid-Atlantic Venture Association’s life science committee, CIT GAP BioLife Fund and University of Alabama-Birmingham’s Concept Fund. He also is active with the technology transfer efforts of numerous universities, including University of Alabama-Birmingham, University of Florida, University of North Carolina, University of Virginia, Georgia Institute of Technology and Duke University.
Before joining HMC, he was employed by BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX), where he served as Vice President of Corporate Development. While there, he managed in- and out-licensing of products and technologies to execute research, discovery functions and commercialization strategies; coordinated contractual arrangements with corporate partners and developed and maintained relationships with the biotech industry and academic research institutions. He was also employed with Genentech, Inc. for twelve years and served in numerous positions, including as Director of Special Markets/Managed Care, where he directed a multi-state domestic and international region, focusing on managed care organizations, insurance companies, HMO’s and Integrated Networks. Before joining Genentech, Mr. Uhrin spent ten years at Eli Lilly & Company.
He received a Bachelor of Science degree in Pharmacy from the University of North Carolina at Chapel Hill and is currently a registered pharmacist in the State of North Carolina.
.